The Head and Neck Cancer Drug Development Summit is dedicated to helping optimize your clinical program in targeted, immune, and combination therapies. Designed to explore how leaders in the space are improving clinical trial design, precision oncology, patient groups, and more to beat the long-standing disparity of where head and neck cancer drugs are and where such therapies should be.  

Building on recent progress and approvals for targeted and immunotherapy agents in head and neck cancer indications, register interest for this biopharma-led forum to learn from industry pioneers, network with key senior decision-makers, and identify the next therapeutic opportunities in head and neck cancers.